. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology. 2012 Mar 6;78(10):709-19. Epub 2012 Feb 22 PubMed.

AlzBiomarker Database

Meta-Analysis

Curated Study Data

Biomarker
(Source)
Cohort
(N)
Measurement
Mean ± SD
Method;
Assay Name;
Manufacturer
Diagnostic
Criteria
Aβ1-42
(CSF)
AD
(60)
372 ± 18†
pg/mL
ELISA;
Innotest;
Innogenetics
Morris et al., 2006; Berg et al., 1998
Aβ1-42
(CSF)
CTRL-
CNC
(211)
615 ± 17†
pg/mL
ELISA;
Innotest;
Innogenetics
VLP-1
(CSF)
AD
(60)
536 ± 26†
pg/mL
Single Molecule Counting Immunoassay;
Erenna;
Singulex, Inc.
Morris et al., 2006; Berg et al., 1998
VLP-1
(CSF)
CTRL-
CNC
(211)
396 ± 10†
pg/mL
Single Molecule Counting Immunoassay;
Erenna;
Singulex, Inc.
tau-p181
(CSF)
AD
(60)
89 ± 6†
pg/mL
ELISA;
Innotest;
Innogenetics
Morris et al., 2006; Berg et al., 1998
tau-p181
(CSF)
CTRL-
CNC
(211)
54 ± 2†
pg/mL
ELISA;
Innotest;
Innogenetics
tau-total
(CSF)
AD
(60)
576 ± 35†
pg/mL
ELISA;
Innotest;
Innogenetics
Morris et al., 2006; Berg et al., 1998
tau-total
(CSF)
CTRL-
CNC
(211)
295 ± 11†
pg/mL
ELISA;
Innotest;
Innogenetics

† Mean ± SEM

Recommends

Please login to recommend the paper.

Comments

Make a Comment

Comments on this Paper

  1. This is a thorough paper showing that CSF levels of VILIP-1 carry similar information as total tau. High CSF levels of the protein indicate intense neurodegeneration, which translates into rapid disease progression and cognitive decline. Whereas the information may be similar, it is important to have alternative biomarkers in the AD field. Much effort has lately been directed to biomarker standardization, and from that perspective, total tau assays may be difficult to standardize, given the many isoforms and modifications of the protein. With some luck VILIP-1 might be easier.

Make a Comment

To make a comment you must login or register.